Quest Diagnostics Sars Cov Antibopdy

SARS-CoV-2 IgG ELISA Kit

E4901-100 100 assays
EUR 903.6

Human IgG antibody Laboratories manufactures the quest diagnostics sars cov antibopdy reagents distributed by Genprice. The Quest Diagnostics Sars Cov Antibopdy reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Antibody. Other Quest products are available in stock. Specificity: Quest Category: Diagnostics Group: Sars Cov

SARS-CoV Spike Antibody

0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

0.02 mg
EUR 206.18
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

0.1 mg
EUR 523.7
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

0.02 mg
EUR 206.18
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

0.1 mg
EUR 523.7
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

Sars Cov information

Recombinant Trypanosoma Vivax Diagnostic antigen Protein (aa 21-111) (E. coli) [His]

VAng-Wyb8566-100g 100 µg
EUR 4002
Description: Trypanosoma Vivax Diagnostic antigen protein, recombinant protein.

Recombinant Trypanosoma Vivax Diagnostic antigen Protein (aa 21-111) (E. coli) [His]

VAng-Wyb8566-500g 500 µg
EUR 9794.4
Description: Trypanosoma Vivax Diagnostic antigen protein, recombinant protein.

Recombinant Trypanosoma Vivax Diagnostic antigen Protein (aa 21-111) (Yeast) [His]

VAng-Wyb8567-100g 100 µg
EUR 5652
Description: Trypanosoma Vivax Diagnostic antigen protein, recombinant protein.

Recombinant Trypanosoma Vivax Diagnostic antigen Protein (aa 21-111) (Yeast) [His]

VAng-Wyb8567-500g 500 µg
EUR 14743.2
Description: Trypanosoma Vivax Diagnostic antigen protein, recombinant protein.

FILTER TIP 1100UL CONDUCTIVITY - TYPE QIAGEN AND DIAGNOSTIC,STERILE,96/1536

QTF-1100-CBK-R-S 1536/pk
EUR 286.8
Description: Robotic Tips; Robotic tips - Axygen

TIP 300UL CONDUCTIVITY - TYPE QIAGEN AND DIAGNOSTIC INSTRUMENTS,NONSTERILE,96/2304

QT-300-CBK-R 2304/pk
EUR 282
Description: Robotic Tips; Robotic tips - Axygen

Recombinant Echinococcus Granulosus hydatid disease diagnostic antigen P-29 Protein (aa 1-238)

VAng-Ly4010-1mgEcoli 1 mg (E. coli)
EUR 4464
Description: Echinococcus Granulosus hydatid disease diagnostic antigen P-29, recombination protein.

Recombinant Echinococcus Granulosus hydatid disease diagnostic antigen P-29 Protein (aa 1-238)

VAng-Ly4010-500gEcoli 500 µg (E. coli)
EUR 3178.8
Description: Echinococcus Granulosus hydatid disease diagnostic antigen P-29, recombination protein.

Recombinant Echinococcus Granulosus hydatid disease diagnostic antigen P-29 Protein (aa 1-238)

VAng-Ly4010-50gEcoli 50 µg (E. coli)
EUR 2172
Description: Echinococcus Granulosus hydatid disease diagnostic antigen P-29, recombination protein.

SARS-CoV-2 Antigen ELISA Kit

DEIA2020 96 tests
EUR 1086
Description: SARS-CoV-2 Antigen ELISA Kit intended use is for quantitative detection of the recombinant SARS-COV-2 nucleoprotein antigen in human serum. The use of this kit for natural samples need to be validated by the end user due to the complexity of natural targets and unpredictable interference.

SARS-CoV-2 Rapid Antigen Test Nasal

9901-NCOV-03G 25 Tests/Kit
EUR 112.8
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke

Recombinant (E.Coli) SARS-CoV Nucleocapsid (1-422)

RP-1416 10 ug
EUR 270

SARS CoV E Protein

abx060650-1mg 1 mg
EUR 2030.4

SARS CoV-2 PCR kit

PCR-H731-48R 48T
EUR 987.6

SARS CoV-2 PCR kit

PCR-H731-96R 96T
EUR 1335.6

SARS CoV Nucleocapsid Protein

abx060652-1mg 1 mg
EUR 2247.6

SARS-CoV-2 (COVID-19) NSP7 Antibody

9155-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers.